

## EXHIBIT C TO PETITION

### Remarks

The above amendments to the specification and the claims are being made to correct inadvertent typographical errors in the specification and more clearly and distinctly claim what Applicant regards as the invention

In particular, paragraph 0022 of the specification is being amended to correct an inadvertent typographical error, namely to correct the spelling of the Argentinian corporation from “Syntax” S.A. to Syntex S.A. No new matter is being added by the amendment.

Paragraph 0035 of the specification is likewise being amended to correct an inadvertent typographical error and for clarity, namely to clarify that N acetyl D-glucosamine is a glucosaminoglycan precursor. Support for the amendment can be found throughout the specification, *e.g.*, at paragraph 0046 which correctly notes that N acetyl D-glucosamine is a polysaccharide that is a precursor to hyaluronic acid, keratin sulfate and chondroitin sulfate. Thus, no new matter is being added by the amendment to paragraph 0035.

Claim 1 is being amended for clarity and to distinctly point out what applicant regards as the invention. In particular, claim 1 has been amended to clarify that the composition of claim 1 is adapted for intra-articular administration. As set forth in the discussion of the references set forth in the Information Disclosure Statement (IDS) that

## EXHIBIT C TO PETITION

is being submitted concurrently herewith as Exhibit B to the “Petition to Make Special”, none of the art of record teaches or suggests the composition of amended claim 1.

Support for the amendment can be found throughout the specification, *e.g.*, at paragraph 0033. Thus, no new matter is being added by the amendment.

Claim 10 is being amended for clarity and to distinctly point out what applicant regards as the invention. In particular, claim 10 has been amended to clarify that the composition of claim 10 is adapted for parenteral administration. As set forth in the discussion of the references in the IDS, none of the art of record teaches or suggests the composition of amended claim 10. Support for the amendment can be found throughout the specification, *e.g.*, at paragraph 0043. Thus, no new matter is being added by the amendment.

As noted, the above amendments correct the typographical errors and, are believed to clearly and distinctly claim the invention and distinguish over the art of record, thereby placing the application in condition for allowance. No additional fee is believed to be due. However, however, the Commissioner is hereby authorized to debit Deposit Account Number 19-4430 for any additional fees deemed to be due.


Expedited entry of the amendment and review pursuant to the accompanying petition is believed to be warranted and is respectfully requested. The Examiner is encouraged to directly contact the undersigned attorney if such contact will enhance the

EXHIBIT C TO PETITION

efficient prosecution of the application to issue.

Respectfully submitted,

STOCKWELL & ASSOCIATES



J.W. Seanor, D.V.M.  
Registration No. 40,804

861 Corporate Drive, Suite 201  
Lexington, Kentucky 40503  
(859) 223-3400

Certificate of Mailing

I hereby certify that this correspondence  
is being deposited with the United States Postal  
Service as Regular Mail in an envelope addressed to:

Commissioner for Patents  
P.O. Box 1450  
Alexandria, Virginia 22313-1450,

November 2, 2004

Date

By

